AntimicrobialResearch Phase

Magainin 2

Topical

Overview

Magainin 2 is a 23-amino acid antimicrobial peptide originally isolated from the skin of the African clawed frog Xenopus laevis. It exerts broad-spectrum antimicrobial activity through membrane disruption, forming pores in bacterial membranes while exhibiting relative selectivity over mammalian cells.

Mechanism of Action

Magainin 2 belongs to the alpha-helical cationic antimicrobial peptide family and has served as a template for numerous synthetic analogs. Its mechanism of action, which is distinct from conventional antibiotics, offers potential against multidrug-resistant pathogens..

Research Summary & Key Findings

Early preclinical studies demonstrated activity against gram-positive and gram-negative bacteria, fungi, and protozoa in vitro and in animal infection models. Clinical development of magainin 2 itself was limited due to modest potency and susceptibility to proteolytic degradation. Derivatives such as pexiganan were subsequently developed to improve stability and therapeutic potential.

Clinical Status

Research Phase

Magainin 2 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Topical

Related Peptides in Antimicrobial

Find a Provider

Find a verified provider who offers Magainin 2 therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Magainin 2.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.